These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 15599319

  • 1. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients.
    Vítko S, Margreiter R, Weimar W, Dantal J, Viljoen HG, Li Y, Jappe A, Cretin N, RAD B201 Study Group.
    Transplantation; 2004 Nov 27; 78(10):1532-40. PubMed ID: 15599319
    [Abstract] [Full Text] [Related]

  • 2. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study.
    Lorber MI, Mulgaonkar S, Butt KM, Elkhammas E, Mendez R, Rajagopalan PR, Kahan B, Sollinger H, Li Y, Cretin N, Tedesco H, B251 Study Group.
    Transplantation; 2005 Jul 27; 80(2):244-52. PubMed ID: 16041270
    [Abstract] [Full Text] [Related]

  • 3. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients.
    Vítko S, Margreiter R, Weimar W, Dantal J, Kuypers D, Winkler M, Øyen O, Viljoen HG, Filiptsev P, Sadek S, Li Y, Cretin N, Budde K, RAD B201 Study Group.
    Am J Transplant; 2005 Oct 27; 5(10):2521-30. PubMed ID: 16162203
    [Abstract] [Full Text] [Related]

  • 4. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
    Sollinger HW.
    Transplantation; 1995 Aug 15; 60(3):225-32. PubMed ID: 7645033
    [Abstract] [Full Text] [Related]

  • 5. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study.
    Viganò M, Dengler T, Mattei MF, Poncelet A, Vanhaecke J, Vermes E, Kleinloog R, Li Y, Gezahegen Y, Delgado JF, RAD A2411 Study Investigators.
    Transpl Infect Dis; 2010 Feb 15; 12(1):23-30. PubMed ID: 19744284
    [Abstract] [Full Text] [Related]

  • 6. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group.
    Mycophenolate Mofetil Acute Renal Rejection Study Group.
    Transplantation; 2001 Apr 27; 71(8):1091-7. PubMed ID: 11374408
    [Abstract] [Full Text] [Related]

  • 7. Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial.
    Eisen HJ, Kobashigawa J, Starling RC, Pauly DF, Kfoury A, Ross H, Wang SS, Cantin B, Van Bakel A, Ewald G, Hirt S, Lehmkuhl H, Keogh A, Rinaldi M, Potena L, Zuckermann A, Dong G, Cornu-Artis C, Lopez P.
    Am J Transplant; 2013 May 27; 13(5):1203-16. PubMed ID: 23433101
    [Abstract] [Full Text] [Related]

  • 8. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
    Transplantation; 1996 Apr 15; 61(7):1029-37. PubMed ID: 8623181
    [Abstract] [Full Text] [Related]

  • 9. Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study.
    Uchida J, Machida Y, Iwai T, Kuwabara N, Kabei K, Naganuma T, Kumada N, Kawashima H, Nakatani T.
    Clin Transplant; 2014 Jan 15; 28(1):80-7. PubMed ID: 24329776
    [Abstract] [Full Text] [Related]

  • 10. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.
    Flechner SM, Goldfarb D, Solez K, Modlin CS, Mastroianni B, Savas K, Babineau D, Kurian S, Salomon D, Novick AC, Cook DJ.
    Transplantation; 2007 Apr 15; 83(7):883-92. PubMed ID: 17460558
    [Abstract] [Full Text] [Related]

  • 11. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients.
    Lehmkuhl HB, Arizon J, Viganò M, Almenar L, Gerosa G, Maccherini M, Varnous S, Musumeci F, Hexham JM, Mange KC, Livi U, 2411 Study Investigators.
    Transplantation; 2009 Jul 15; 88(1):115-22. PubMed ID: 19584690
    [Abstract] [Full Text] [Related]

  • 12. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation.
    Cibrik D, Silva HT, Vathsala A, Lackova E, Cornu-Artis C, Walker RG, Wang Z, Zibari GB, Shihab F, Kim YS.
    Transplantation; 2013 Apr 15; 95(7):933-42. PubMed ID: 23422495
    [Abstract] [Full Text] [Related]

  • 13. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: The Mycophenolate Mofetil Acute Renal Rejection Study Group.
    Transplantation; 1998 Jan 27; 65(2):235-41. PubMed ID: 9458021
    [Abstract] [Full Text] [Related]

  • 14. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. The Mycophenolate Mofetil Renal Refractory Rejection Study Group.
    Transplantation; 1996 Mar 15; 61(5):722-9. PubMed ID: 8607174
    [Abstract] [Full Text] [Related]

  • 15. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups.
    Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C.
    Transplantation; 1997 Jan 15; 63(1):39-47. PubMed ID: 9000658
    [Abstract] [Full Text] [Related]

  • 16. Economic evaluation of everolimus and mycophenolate mofetil versus azathioprine in de novo heart transplantation.
    Annemans L, Lemkuhl H, Tenderich G, Schulz U, Yang XL, Ricci JF, Hetzer R.
    Transplant Proc; 2007 Dec 15; 39(10):3306-12. PubMed ID: 18089377
    [Abstract] [Full Text] [Related]

  • 17. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. European Mycophenolate Mofetil Cooperative Study Group.
    Transplantation; 1999 Aug 15; 68(3):391-6. PubMed ID: 10459543
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data.
    Qazi Y, Shaffer D, Kaplan B, Kim DY, Luan FL, Peddi VR, Shihab F, Tomlanovich S, Yilmaz S, McCague K, Patel D, Mulgaonkar S.
    Am J Transplant; 2017 May 15; 17(5):1358-1369. PubMed ID: 27775865
    [Abstract] [Full Text] [Related]

  • 19. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.
    Kreis H, Cisterne JM, Land W, Wramner L, Squifflet JP, Abramowicz D, Campistol JM, Morales JM, Grinyo JM, Mourad G, Berthoux FC, Brattström C, Lebranchu Y, Vialtel P.
    Transplantation; 2000 Apr 15; 69(7):1252-60. PubMed ID: 10798738
    [Abstract] [Full Text] [Related]

  • 20. Rescue therapy with mycophenolate mofetil. The Mycophenolate Mofetil Renal Refractory Rejection Study Group.
    Clin Transplant; 1996 Feb 15; 10(1 Pt 2):131-5. PubMed ID: 8680050
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.